Drug intelligence / Profile preview

NKTR-0166

Development stage: Preclinical
Lead developer: Nektar Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NKTR-0166 is a bispecific antibody being developed by Nektar Therapeutics for the treatment of autoimmune disorders. The drug acts as an agonist of the type II tumour necrosis factor receptor (TNFR2), aiming to modulate immune responses by stimulating this receptor, which is associated with regulatory T cell function and immune tolerance. As of February 2025, NKTR-0166 remains in preclinical development and has not been designated as an orphan drug or a new molecular entity[1][9].

Targets

TNFR2 (Tumor necrosis factor receptor superfamily member 1B)

Beyond the preview

Go deeper on NKTR-0166.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKTR-0166.

Explore the full profile